Contineum Therapeutics, Inc. Class A Common Stock
Veridion Score
BETAMEDIUM CONF · 5/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is CTNM moving today?
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
CTNM overview
Related filings and maps
Congress activity in CTNM
No receipt-qualified Congressional disclosure is present for CTNM in the cached public ledger.
CTNM contract awards, year to date.
Public federal awards linked to this ticker.
CTNM lobbying filings, year to date.
Registered lobbying filings matched to Contineum Therapeutics, Inc. Class A Common Stock.